• About us
• Contact

Advertisement

Person › Details

Erich Tauber (Themis Bioscience GmbH)

Tauber, Erich (Themis Bioscience GmbH 201505 CEO)

 

	Organisation	Themis Bioscience GmbH
	Group	Merck (US) (MSD) (Group)
	Product	vaccine

Record changed: 2020-05-26

Advertisement

More documents for Erich Tauber

• [1] Merck & Co., Inc.. (5/26/20). "Press Release: Merck to Acquire Themis". Kenilworth, NJ....
• [2] Themis Bioscience GmbH. (10/29/19). "Press Release: Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine". Vienna & Oslo....
• [3] Themis Bioscience GmbH. (9/18/19). "Press Release: Themis Raises EUR 40 Million in Series D Financing Round Backed by US/EU Consortium to Support Pivotal Study and Expand Clinical Pipeline". Vienna....
• [4] Themis Bioscience GmbH. (8/22/19). "Press Release: Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates". Vienna....
• [5] Themis Bioscience GmbH. (6/4/19). "Press Release: CEPI Awards up to US$21 Million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development". Vienna & Oslo....
• [6] Themis Bioscience GmbH. (2/25/19). "Press Release: Themis Bioscience Receives FDA Fast Track Designation for Chikungunya Vaccine Candidate". Vienna....
• [7] Themis Bioscience N.V.. (11/8/18). "Press Release: Themis Bioscience Postpones Its Listing on Euronext Amsterdam [Not for United States, Canada, Australia or Japan or any other jurisdiction where unlawful]". Vienna....
• [8] Themis Bioscience GmbH. (11/5/18). "Press Release: Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in The Lancet". Vienna....
• [9] Themis Bioscience N.V.. (10/29/18). "Press Release: Themis Bioscience Launches its Initial Public Offering on Euronext Amsterdam [Not for United States, Canada, Australia or Japan or any other jurisdiction where unlawful]". Vienna....
• [10] Themis Bioscience GmbH. (6/11/18). "Press Release: Themis Receives EMA PRIME Designation for Chikungunya Vaccine". Vienna....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.